<p>Intellia Therapeutics（納斯達克股票代碼：NTLA - 獲取免費報告）於週一公佈了季度財報。該公司報告每股收益（EPS）為（$0.81），超出分析師一致預期的（$0.92）$0.11，FiscalAI 報道。Intellia Therapeutics 的淨利潤率為負 609.85%，股本回報率為負 56.81%。該公司本季度的收入為 1505 萬美元，而分析師的預期為 1381 萬美元。</p>
<p>獲取 <strong>Intellia Therapeutics</strong> 的提醒：</p>
<h2>Intellia Therapeutics 價格表現</h2>
<ul>
<li>3 只可能受益於專利懸崖的生物科技股票</li>
</ul>
<p>週一中午交易時，NTLA 股票上漲了$0.64，達到了$14.73。該公司的股票交易量為 4,126,629 股，而其平均交易量為 5,303,502 股。Intellia Therapeutics 的 12 個月最低價為$6.83，最高價為$28.25。該公司的 50 日移動平均價格為$13.65，200 日移動平均價格為$12.41。該股票的市值為 17.7 億美元，市盈率為-3.84，貝塔值為 1.93。</p>
<h2>分析師評級上調與下調</h2>
<p>多家券商對 NTLA 發佈了報告。Truist Financial 在 3 月 25 日的研究報告中將 Intellia Therapeutics 的股票評級上調至 “強力買入”。William Blair 在 3 月 2 日的研究報告中將 Intellia Therapeutics 的股票評級從 “市場表現” 上調至 “跑贏大盤”。Robert W. Baird 在 4 月 27 日的研究報告中將 Intellia Therapeutics 的目標價從$7.00 上調至$13.00，並給予該公司 “中性” 評級。HC Wainwright 在 3 月 3 日的研究報告中將 Intellia Therapeutics 的目標價從$25.00 上調至$30.00，並給予該公司 “買入” 評級。最後，KeyCorp 在 1 月 28 日的研究報告中對 Intellia Therapeutics 設定了$25.00 的目標價。一位股票研究分析師將該股票評級為強力買入，九位分析師給予買入評級，十位分析師給予持有評級，三位分析師給予賣出評級。根據 MarketBeat.com 的數據，Intellia Therapeutics 的平均評級為 “持有”，平均目標價為$20.55。</p>
<ul>
<li>高盛在其看漲的標普 500 展望中關注這 3 只股票</li>
</ul>
<p><strong>查看我們最新的 Intellia Therapeutics 股票報告</strong></p>
<h2>機構投資者對 Intellia Therapeutics 的看法</h2>
<p>對沖基金和其他機構投資者最近增加或減少了對該公司的持股。Virtu Financial LLC 在第四季度收購了 Intellia Therapeutics 的新頭寸，價值約為$245,000。Invesco Ltd.在第四季度將其在 Intellia Therapeutics 的持股增加了 5.8%。Invesco Ltd.目前擁有 433,290 股該公司的股票，價值$3,895,000，此前在上個季度又購買了 23,870 股。Axxcess Wealth Management LLC 在第四季度將其在 Intellia Therapeutics 的持股增加了 20.1%。Axxcess Wealth Management LLC 目前擁有 21,399 股該公司的股票，價值$192,000，此前在上個季度又購買了 3,583 股。Mercer Global Advisors Inc. ADV 在第四季度收購了 Intellia Therapeutics 的新頭寸，價值約為$90,000。最後，XTX Topco Ltd 在第四季度收購了 Intellia Therapeutics 的新頭寸，價值約為$402,000。目前 88.77% 的股票由機構投資者和對沖基金持有。</p>
<h2>Intellia Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<ul>
<li>分析師認為這些股票的價值可能翻倍</li>
</ul>
<p>Intellia Therapeutics, Inc. 納斯達克：NTLA 是一家臨牀階段的生物科技公司，專注於開發潛在的治癒性基因編輯療法，使用 CRISPR/Cas9 平台。該公司的研究涵蓋了 CRISPR/Cas9 的體內和體外應用，旨在通過一次給藥糾正或禁用致病基因。Intellia 的主要體內項目針對轉甲狀腺素澱粉樣變（ATTR），通過將 CRISPR/Cas9 機制直接輸送到肝臟，而其他的臨牀前努力則追求治療血友病 A、遺傳性血管水腫和其他遺傳疾病。</p>
<p>除了其體內管線，Intellia 還與戰略合作伙伴合作，以擴大其基因編輯方法的影響。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票超過 Intellia Therapeutics</li>
<li>AI 分紅增加：3 只巨頭股票提升分紅</li>
<li>瘋狂的週一：這家 SaaS 領導者的反彈只是個開始</li>
<li>5 只有望受益於 AI 推理熱潮的股票</li>
<li>Meta Platforms 的財報後劇烈波動：分析師的目標價現狀</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRMQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRMQQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Intellia Therapeutics 嗎？</h2>
<p>在你考慮投資 Intellia Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Intellia Therapeutics 並不在名單上。</p>
<p>雖然 Intellia Therapeutics 目前在分析師中評級為持有，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Intellia治療

CRISPR治療

基因免疫&健康關懷 ETF - iShares

<p>Intellia Therapeutics（納斯達克代碼：NTLA）報告的季度每股收益為（$0.81），超出預期的（$0.92）$0.11。該公司的收入為 1505 萬美元，超過預期的 1381 萬美元。Intellia 的淨利潤率為-609.85%，股本回報率為-56.81%。股票交易價格上漲至$14.73，市值為 17.7 億美元。分析師的評級各不相同，其中一項為強烈買入，九項為買入，十項為持有，三項為賣出。機構投資者持有該股票的 88.77%，公司專注於 CRISPR/Cas9 基因編輯療法</p>

<p>Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.92) by $0.11, FiscalAI reports. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The firm had revenue of $15.05 million for the quarter, compared to analysts' expectations of $13.81 million.</p>
<div class="lb-trans"><p>Intellia Therapeutics（納斯達克股票代碼：NTLA - 獲取免費報告）於週一公佈了季度財報。該公司報告每股收益（EPS）為（$0.81），超出分析師一致預期的（$0.92）$0.11，FiscalAI 報道。Intellia Therapeutics 的淨利潤率為負 609.85%，股本回報率為負 56.81%。該公司本季度的收入為 1505 萬美元，而分析師的預期為 1381 萬美元。</p>
</div><p>Get <strong>Intellia Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Intellia Therapeutics</strong> 的提醒：</p>
</div><h2>Intellia Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Intellia Therapeutics 價格表現</h2>
</div><ul>
<li>3 Biotech Stocks That Could Benefit from the Patent Cliff</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只可能受益於專利懸崖的生物科技股票</li>
</ul>
</div><p>NTLA stock traded up $0.64 during midday trading on Monday, hitting $14.73. The company's stock had a trading volume of 4,126,629 shares, compared to its average volume of 5,303,502. Intellia Therapeutics has a twelve month low of $6.83 and a twelve month high of $28.25. The company's fifty day moving average price is $13.65 and its 200 day moving average price is $12.41. The stock has a market capitalization of $1.77 billion, a P/E ratio of -3.84 and a beta of 1.93.</p>
<div class="lb-trans"><p>週一中午交易時，NTLA 股票上漲了$0.64，達到了$14.73。該公司的股票交易量為 4,126,629 股，而其平均交易量為 5,303,502 股。Intellia Therapeutics 的 12 個月最低價為$6.83，最高價為$28.25。該公司的 50 日移動平均價格為$13.65，200 日移動平均價格為$12.41。該股票的市值為 17.7 億美元，市盈率為-3.84，貝塔值為 1.93。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調與下調</h2>
</div><p>A number of brokerages have issued reports on NTLA. Truist Financial raised shares of Intellia Therapeutics to a &#34;strong-buy&#34; rating in a research note on Wednesday, March 25th. William Blair raised shares of Intellia Therapeutics from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating in a research note on Monday, March 2nd. Robert W. Baird raised their price objective on shares of Intellia Therapeutics from $7.00 to $13.00 and gave the company a &#34;neutral&#34; rating in a research note on Monday, April 27th. HC Wainwright raised their price objective on shares of Intellia Therapeutics from $25.00 to $30.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, March 3rd. Finally, KeyCorp set a $25.00 price target on shares of Intellia Therapeutics in a research report on Wednesday, January 28th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Intellia Therapeutics has an average rating of &#34;Hold&#34; and an average target price of $20.55.</p>
<div class="lb-trans"><p>多家券商對 NTLA 發佈了報告。Truist Financial 在 3 月 25 日的研究報告中將 Intellia Therapeutics 的股票評級上調至 “強力買入”。William Blair 在 3 月 2 日的研究報告中將 Intellia Therapeutics 的股票評級從 “市場表現” 上調至 “跑贏大盤”。Robert W. Baird 在 4 月 27 日的研究報告中將 Intellia Therapeutics 的目標價從$7.00 上調至$13.00，並給予該公司 “中性” 評級。HC Wainwright 在 3 月 3 日的研究報告中將 Intellia Therapeutics 的目標價從$25.00 上調至$30.00，並給予該公司 “買入” 評級。最後，KeyCorp 在 1 月 28 日的研究報告中對 Intellia Therapeutics 設定了$25.00 的目標價。一位股票研究分析師將該股票評級為強力買入，九位分析師給予買入評級，十位分析師給予持有評級，三位分析師給予賣出評級。根據 MarketBeat.com 的數據，Intellia Therapeutics 的平均評級為 “持有”，平均目標價為$20.55。</p>
</div><ul>
<li>Goldman Spotlights These 3 Stocks in Its Bullish S&amp;P 500 Outlook</li>
</ul>
<div class="lb-trans"><ul>
<li>高盛在其看漲的標普 500 展望中關注這 3 只股票</li>
</ul>
</div><p><strong>View Our Latest Stock Report on Intellia Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 Intellia Therapeutics 股票報告</strong></p>
</div><h2>Institutional Investors Weigh In On Intellia Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Intellia Therapeutics 的看法</h2>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in shares of Intellia Therapeutics during the 4th quarter worth about $245,000. Invesco Ltd. increased its stake in shares of Intellia Therapeutics by 5.8% during the 4th quarter. Invesco Ltd. now owns 433,290 shares of the company's stock worth $3,895,000 after purchasing an additional 23,870 shares during the last quarter. Axxcess Wealth Management LLC increased its stake in shares of Intellia Therapeutics by 20.1% during the 4th quarter. Axxcess Wealth Management LLC now owns 21,399 shares of the company's stock worth $192,000 after purchasing an additional 3,583 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in shares of Intellia Therapeutics during the 4th quarter worth about $90,000. Finally, XTX Topco Ltd acquired a new position in shares of Intellia Therapeutics during the 4th quarter worth about $402,000. 88.77% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>對沖基金和其他機構投資者最近增加或減少了對該公司的持股。Virtu Financial LLC 在第四季度收購了 Intellia Therapeutics 的新頭寸，價值約為$245,000。Invesco Ltd.在第四季度將其在 Intellia Therapeutics 的持股增加了 5.8%。Invesco Ltd.目前擁有 433,290 股該公司的股票，價值$3,895,000，此前在上個季度又購買了 23,870 股。Axxcess Wealth Management LLC 在第四季度將其在 Intellia Therapeutics 的持股增加了 20.1%。Axxcess Wealth Management LLC 目前擁有 21,399 股該公司的股票，價值$192,000，此前在上個季度又購買了 3,583 股。Mercer Global Advisors Inc. ADV 在第四季度收購了 Intellia Therapeutics 的新頭寸，價值約為$90,000。最後，XTX Topco Ltd 在第四季度收購了 Intellia Therapeutics 的新頭寸，價值約為$402,000。目前 88.77% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Intellia Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Intellia Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><ul>
<li>Analysts Think These Stocks Could More Than Double in Value</li>
</ul>
<div class="lb-trans"><ul>
<li>分析師認為這些股票的價值可能翻倍</li>
</ul>
</div><p>Intellia Therapeutics, Inc NASDAQ: NTLA is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company's research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia's lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.</p>
<div class="lb-trans"><p>Intellia Therapeutics, Inc. 納斯達克：NTLA 是一家臨牀階段的生物科技公司，專注於開發潛在的治癒性基因編輯療法，使用 CRISPR/Cas9 平台。該公司的研究涵蓋了 CRISPR/Cas9 的體內和體外應用，旨在通過一次給藥糾正或禁用致病基因。Intellia 的主要體內項目針對轉甲狀腺素澱粉樣變（ATTR），通過將 CRISPR/Cas9 機制直接輸送到肝臟，而其他的臨牀前努力則追求治療血友病 A、遺傳性血管水腫和其他遺傳疾病。</p>
</div><p>Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.</p>
<div class="lb-trans"><p>除了其體內管線，Intellia 還與戰略合作伙伴合作，以擴大其基因編輯方法的影響。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Intellia Therapeutics</li>
<li>AI Dividend Increases: 3 Massive Winners Boosting Payouts</li>
<li>Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader</li>
<li>5 Stocks Positioned to Benefit From the AI Inference Boom</li>
<li>Meta Platforms’ Wild Post-Earnings Swings: Where Analyst Price Targets Stand Now</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 Intellia Therapeutics</li>
<li>AI 分紅增加：3 只巨頭股票提升分紅</li>
<li>瘋狂的週一：這家 SaaS 領導者的反彈只是個開始</li>
<li>5 只有望受益於 AI 推理熱潮的股票</li>
<li>Meta Platforms 的財報後劇烈波動：分析師的目標價現狀</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRMQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=NTLA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Intellia Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Intellia Therapeutics 嗎？</h2>
</div><p>Before you consider Intellia Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 Intellia Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Intellia Therapeutics 並不在名單上。</p>
</div><p>While Intellia Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Intellia Therapeutics 目前在分析師中評級為持有，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Intellia Therapeutics（納斯達克股票代碼：NTLA）公佈了財務業績